Navigation Links
NUCRYST Announces Management Realignment and R&D Portfolio Change
Date:4/30/2008

rrier cream or for other future products; competition from other silver-based pharmaceutical or medical device companies; our ability to raise additional financing required to fund further research and development, clinical studies and obtain regulatory approvals, on commercially acceptable terms or at all; changes in currency exchange rates; our ability to protect our intellectual property rights and to not infringe on the intellectual property rights of others; our ability to comply with governmental regulations and standards; our ability to successfully attract and retain skilled and experienced personnel; changes in general economic and capital market conditions; other risks and uncertainties unidentified at this time; and management's response to these factors. Although we have attempted to identify the important risks, uncertainties and other factors that could cause actual results or events to differ materially from those expressed or implied in forward-looking statements, there may be other factors that cause actual results or events to differ from those expressed or implied in forward looking statements. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our Annual Report on Form 10-K for the year ended December 31, 2007, filed with the U.S. Securities and Exchange Commission on EDGAR at http://www.sec.gov and with securities authorities in Canada on SEDAR at http://www.sedar.com. All forward-looking statements are expressly qualified in their entirety by this cautionary statement and NUCRYST disclaims any intention or obligation to revise or update any forward-looking statements whether as a result of new information, future developments or otherwise after the date hereof.


'/>"/>
SOURCE NUCRYST Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. NUCRYST Announces Senior Management Change
2. NUCRYST Pharmaceuticals announces year-end results
3. NUCRYST Pharmaceuticals announces 2007 third quarter results
4. Webcast Advisory - NUCRYST Pharmaceuticals Webcast of Conference Call to Discuss 2007 Third Quarter Results
5. NUCRYST and Smith & Nephew Revise Agreements
6. West Pharmaceutical Services, Inc. Announces Annual Meeting Webcast
7. Renowned ENT Specialist, Dr. Murray Grossan, Announces Medical Breakthrough on Snoring at PRI-MED Convention in Anaheim on May 15-17
8. GSK Announces Changes to Corporate Executive Team
9. Summit VetPharm Announces New Distributor Partnership with Webster Veterinary
10. Psychemedics Corporation Announces First Quarter Results
11. InfoLogix Announces First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2008)...tic children whose parents have high expectations ...kely to have symptoms than other children dealing ...dren also are more likely to use asthma controller...for taking medicine and if their parents clearly u... The study, which appears in the Oct. 2008 issue o...
(Date:10/3/2008)...ding is beneficial. But can it help kids lose weig...terature on obese adolescents, researchers at Duke...ight type of novel may make a difference. , The ...who were already in a comprehensive weight loss pr... Rescue (Beacon Street Press). It was carefully cr...
(Date:10/3/2008)... Inc. Magazine recently included,Connolly Consulti...ng,private companies in the country. The list is t...egment of the economy -- America,s,independent-min...es,represent the backbone of the U.S. economy., (...3/NY36880LOGO ), Connolly Consulting,s consisten...
(Date:10/3/2008)...idents to Eat Right, Move More and ...t. 3 /PRNewswire/ -- The last decade can be define...hich seem to go in and out,of fashion like shoulde...en,slim. Two out of three Americans -- including 2...weight or obese., A new campaign crossing the cou...
Breaking Medicine News(10 mins):Health News:Children's asthma affected by parental expectations 2Health News:Duke researchers show reading can help obese kids lose weight 2Health News:Connolly Consulting Makes the 2008 Inc. Magazine's List of America's 5000 Fastest Growing Companies 2Health News:Message to Pennsylvania Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Pennsylvania Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3
...ms of 11 patients with the dreaded genetic conditi...been relieved after liver transplants//. This is t... Children's Hospital of Pittsburgh and the Clinic ... the study (ranging in age from 1-20) are alive an...
...entre of Excellence for Integrative Legume Researc...btain useable nitrogen from soil bacteria// in the...ied a number of compounds, which could potentially...rs. Without an adequate blood supply tumours stop ...
...us, the one that causes mononucleosis, may be a ca...lts with high levels of antibodies//, according to... appear later in June 2006 print issue of Archives... have long suspected that external factors may inf...
...the UK government, requiring work permit to be mad... them to work in the National Health Service// (NH... doctors. With the change in rule, about 4,000 In...e expected to be affected in addition to about 850...
Other Medicine News:Health News:Liver Transplants to the Rescue of Dreaded MSUD disease 2Health News:Compounds In Legume May Be Helpful In Treating Cancer 2Health News:Epstein-Barr Virus May Be May Be A Cause For Multiple Sclerosis 2
(Date:10/6/2008)... - Data Presented at ACG Annual Scientific Confer...nwood Pharmaceuticals,(formerly Microbia) today an...nical studies delineating the role that cyclic gua...ntestinal pain. These studies,demonstrate that cGM...of,intestinal hyperalgesia and desensitizes coloni...
(Date:10/6/2008)...lts from Phase 3b Studies with Durezol Dosed Prior...Sirion Therapeutics, Inc., a,privately held ophtha...today that Durezol(TM) (difluprednate ophthalmic e...zol, which was approved by the U.S. Food and,Drug ...ic corticosteroid,indicated for the treatment of i...
(Date:10/6/2008)...than 60 percent of moderate to severe patients ach... achieved endoscopic remission at Week 10,in data ...merican College,of Gastroenterology (ACG) Annual S...ire/ -- UCB today presented data from a,large, pro...t in Crohn,s,disease (CD) with a biologic compound...
(Date:10/6/2008)...LE, Oct. 6 /- Dendreon Corp... today, Monday, October 6, 2008 at 9:00 AM,ET (6:0...ysis of its IMPACT,(IMmunotherapy for Prostate Ade...cal trial of PROVENGE(R) (sipuleucel-T), the Compa... for the treatment of advanced prostate,cancer., ...
Breaking Medicine Technology:Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 2Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 2Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 2CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 3CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 4CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 6CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 7Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 2Protein Tomography 28TM 29 Reveals Molecular Mode of Action of Humax EGFr Published in PNAS 1869 1Protein Tomography 28TM 29 Reveals Molecular Mode of Action of Humax EGFr Published in PNAS 1869 2Survey 3A Employers Have High Confidence They Can Control Health Care Costs With Proper Tools 17389 1Survey 3A Employers Have High Confidence They Can Control Health Care Costs With Proper Tools 17389 2Survey 3A Employers Have High Confidence They Can Control Health Care Costs With Proper Tools 17389 3TopoTarget Successfully Buys Back Full Control of Belinostat 4752 1TopoTarget Successfully Buys Back Full Control of Belinostat 4752 2TopoTarget Successfully Buys Back Full Control of Belinostat 4752 3TopoTarget Successfully Buys Back Full Control of Belinostat 4752 4TopoTarget Successfully Buys Back Full Control of Belinostat 4752 5TopoTarget Successfully Buys Back Full Control of Belinostat 4752 6TopoTarget Successfully Buys Back Full Control of Belinostat 4752 7Mannatech Launches Business in South Africa 17387 1Mannatech Launches Business in South Africa 17387 2Mannatech Launches Business in South Africa 17387 3
...Presentation Details Statistically Significant Cli...ent of Diabetic Neuropathy, CHICAGO, June 22, 2007...c. announced today the presentation of encouraging...) program at the,67th Scientific Sessions of the A...n an oral presentation entitled, "Improved,Neurolo...
... FOSTER CITY, Calif.--(BUSINESS WIRE)--June 25, 20...unced that Study 103, a,Phase III clinical trial e...iread(R) (tenofovir disoproxil fumarate or tenofov... hepatitis B virus,(HBV) infection, met its primar...non-inferior to the company,s once-daily antiviral...
Other Medicine Technology:Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 2Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 3Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 4Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 5Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 6Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 7Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 8Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 9Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 6
...rt SI inserter from Bausch & Lomb provides fingert...ned for one handed delivery of the IOL directly in...assured by planar delivery. Leading haptic is posi...bag without sweeping motion. No additional instrum...
...erex Ultra Q is the fundamental capsulotmy laser -...ergy delivery and provides 2855% less energy in ai... in contemporary systems. This technology elimina...educes the risk of IOL pitting. , , , Ultr...
Protects the eye during or after surgery or trauma. Clear window dressing. Protects the eye allowing the patient to see.
Product designed specifically for posteror segment surgical procedures. For dissection of vitreoretinal membrames using viscoelastic fluid. A high pressure luer lock tubing set is attached to cannula
Medicine Products: